Description

Nemesis Stack (LGD-4033 + RAD-140 + S23) – Product Information

The Nemesis Stack consists of three selective androgen receptor modulators (SARMs): LGD-4033, RAD-140, and S23. Each SARM has its own unique properties and mechanisms of action. When combined in a stack, LGD-4033, RAD-140, and S23 can be researched together to potentially achieve synergistic effects on muscle growth, strength, and body composition changes.

• Nemesis Stack consists of LGD-4033, RAD-140, and S23.
• Nemesis tablets are offered in 2 variants: 25mg RAD 140, 25mg LGD 4033, and 25mg S23, totaling 75mg per tablet for 20 tablets or 1500mg in total; and 75mg per tablet for 40 tablets or 3000mg in total.
• Nemesis capsules are offered in 25mg RAD 140, 25mg LGD 4033, and 25mg S23, totaling 75mg per capsule for 40 capsules or 3000mg in total.
• The liquid is offered as 33.3mg LGD-4033, 33.3mg RAD-140, and 33.3mg S-23. This totals 100mg per ml for 30ml, or 3000mg in total.

LGD-4033

Ligandrol (LGD 4033) is a novel nonsteroidal oral selective androgen receptor modulator currently being investigated in research as a potential treatment for conditions relating to muscle dystrophy and osteoporosis.

Recent studies investigated the effects of LGD 4033 on muscle tissue in ovariectomized rats. A daily dose of LGD was administered and calculated according to the body weight of each individual rat at the onset of the study. Results and changes were noted as soon as week 2, the control group having weighed significantly less than rats undergoing LGD treatment. This difference remained until the end of the study, irrespective of LGD treatments. Additionally, the LGD treatments resulted in a higher number of capillaries in all muscles studied. Longer randomized trials and research could potentially evaluate its efficacy in improving physical function and health outcomes in select populations.

RAD-140

Testolone, also known as RAD 140, as a research compound is being investigated for its potential ability to enhance muscle hypertrophy. Current studies are examining the preclinical characterization of selective androgen receptor modulators and anabolic activity in male cynomolgus monkeys. To assess anabolic activity, one study examined gross body weight, which we know to be a sensitive marker of anabolic androgen action in young nonhuman primates. The results on animal body weight of 28-day dosing with RAD140 were found to be statistically significant. This shows massive promise in the potential muscular gains brought on by Testolone.

S23

According to the available studies, S23 induced infertility in all rats it was exposed to. These effects are dose-dependent and temporary, meaning the rats regained fertility following treatment. This shows the potential of S23 as an oral male contraceptive.

According to the research, S23 subdues serum concentration of luteinizing hormone and follicle-stimulating hormone to produce biphasic effects on spermatogenesis. Additional research and clinical trials should be conducted to determine the efficacy and safety of S23 is as an oral contraceptive.

The above-mentioned study produced other beneficial desirable effects. For instance, researchers observed a stronger affinity to androgen receptors as compared to other popular compounds like Andarine. It also has an ideal anabolic-androgenic ratio allowing it to produce a good number of positive effects without any severe complications. One of those effects was increasing bone mineral density and lean muscle mass.